Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madlen Jentzsch

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|March 12, 2025
Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcomeLara Bischof, Jule Ussmann, Uwe Platzbecker, et al.
Current Treatment Options in Oncology|February 1, 2020
Use of Minimal Residual Disease in Acute Myeloid Leukemia TherapySebastian Schwind, Madlen Jentzsch, Enrica Bach, et al.
Neoplasia (New York, N.Y.)|October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscapeSebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.
Cancers|October 27, 2019
Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid LeukemiaMadlen Jentzsch, Sebastian Schwind, Enrica Bach, et al.
Pediatric Blood & Cancer|January 28, 2015
Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adultsIvonne Wieland, Karim Kentouche, Madlen Jentzsch, et al.
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|March 9, 2019
[Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]Madlen Jentzsch, Sebastian Schwind, Vladan Vucinic, et al.
Blood Advances|August 19, 2020
Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Hemasphere|February 22, 2021
Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell TransplantationDominic Brauer, Donata Backhaus, Rosmarie Pointner, et al.
Cancers|February 25, 2023
Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell TransplantationMadlen Jentzsch, Lara Bischof, Dominic Brauer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 2019
Pretreatment CD34<sup>+</sup>/CD38<sup>-</sup> Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell TransplantationMadlen Jentzsch, Ulrike Geus, Juliane Grimm, et al.
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|March 12, 2025
Allogeneic stem cell transplantation for MDS-clinical issues, choosing preparative regimens and outcomeLara Bischof, Jule Ussmann, Uwe Platzbecker, et al.
Current Treatment Options in Oncology|February 1, 2020
Use of Minimal Residual Disease in Acute Myeloid Leukemia TherapySebastian Schwind, Madlen Jentzsch, Enrica Bach, et al.
Neoplasia (New York, N.Y.)|October 3, 2021
Myelodysplastic syndromes: Biological and therapeutic consequences of the evolving molecular aberrations landscapeSebastian Schwind, Madlen Jentzsch, Anne Sophie Kubasch, et al.
Cancers|October 27, 2019
Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid LeukemiaMadlen Jentzsch, Sebastian Schwind, Enrica Bach, et al.
Pediatric Blood & Cancer|January 28, 2015
Long-term remission of recurrent thrombotic thrombocytopenic purpura (TTP) after Rituximab in children and young adultsIvonne Wieland, Karim Kentouche, Madlen Jentzsch, et al.
Medizinische Klinik, Intensivmedizin Und Notfallmedizin|March 9, 2019
[Meningococcal sepsis without cerebrospinal fluid abnormalities under treatment with eculizumab]Madlen Jentzsch, Sebastian Schwind, Vladan Vucinic, et al.
Blood Advances|August 19, 2020
Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantationJuliane Grimm, Madlen Jentzsch, Marius Bill, et al.
Hemasphere|February 22, 2021
Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients Following Allogeneic Stem Cell TransplantationDominic Brauer, Donata Backhaus, Rosmarie Pointner, et al.
Cancers|February 25, 2023
Clinical Implications of the <i>FLT3</i>-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell TransplantationMadlen Jentzsch, Lara Bischof, Dominic Brauer, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 2019
Pretreatment CD34<sup>+</sup>/CD38<sup>-</sup> Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell TransplantationMadlen Jentzsch, Ulrike Geus, Juliane Grimm, et al.
Pageof 7